Cargando…

An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential GSK3β/β-Catenin/STAT3/CD44 Suppressor with Anti-Glioblastoma Properties

Despite management efforts with standard surgery, radiation, and chemotherapy, glioblastoma multiform (GBM) remains resistant to treatment, which leads to tumor recurrence due to glioma stem cells (GSCs) and therapy resistance. In this study, we used random computer-based prediction and target ident...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mokgautsi, Ntlotlang, Wen, Ya-Ting, Lawal, Bashir, Khedkar, Harshita, Sumitra, Maryam Rachmawati, Wu, Alexander T. H., Huang, Hsu-Shan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957701/ https://www.ncbi.nlm.nih.gov/pubmed/33671112 http://dx.doi.org/10.3390/ijms22052464

Ejemplares similares

Network Pharmacological Analysis through a Bioinformatics Approach of Novel NSC765600 and NSC765691 Compounds as Potential Inhibitors of CCND1/CDK4/PLK1/CD44 in Cancer Types
por: Mokgautsi, Ntlotlang, et al.
Publicado: (2021)

Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines
por: Lawal, Bashir, et al.
Publicado: (2021)

mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2′,4′-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications
por: Lawal, Bashir, et al.
Publicado: (2021)

In-Silico Evaluation of Genetic Alterations in Ovarian Carcinoma and Therapeutic Efficacy of NSC777201, as a Novel Multi-Target Agent for TTK, NEK2, and CDK1
por: Khedkar, Harshita Nivrutti, et al.
Publicado: (2021)

Niclosamide Inhibits Aortic Valve Interstitial Cell Calcification by Interfering with the GSK-3β/β-Catenin Signaling Pathway
por: Adhikari, Radhika, et al.
Publicado: (2023)

In Vitro and In Silico Biological Studies of 4-Phenyl-2-quinolone (4-PQ) Derivatives as Anticancer Agents
por: Chen, Yi-Fong, et al.
Publicado: (2023)

Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β
por: Kaushal, Jyoti B., et al.
Publicado: (2021)

HNC0014, a Multi-Targeted Small-Molecule, Inhibits Head and Neck Squamous Cell Carcinoma by Suppressing c-Met/STAT3/CD44/PD-L1 Oncoimmune Signature and Eliciting Antitumor Immune Responses
por: Lee, Jih-Chin, et al.
Publicado: (2020)

Multiomics Study of a Novel Naturally Derived Small Molecule, NSC772864, as a Potential Inhibitor of Proto-Oncogenes Regulating Cell Cycle Progression in Colorectal Cancer
por: Mokgautsi, Ntlotlang, et al.
Publicado: (2023)

Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent
por: Chinyama, Harold A., et al.
Publicado: (2023)

A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling
por: Wu, Alexander T. H., et al.
Publicado: (2021)

The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression
por: Guo, Yangyang, et al.
Publicado: (2022)

Different expression of GSK3β and pS9GSK3β depending on phenotype of cervical cancer: possible association of GSK3β with squamous cell carcinoma and pS9GSK3β with adenocarcinoma
por: Ahn, Kwanghee, et al.
Publicado: (2019)

Correction: The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression
por: Guo, Yangyang, et al.
Publicado: (2022)

GSK3β Is Involved in JNK2-Mediated β-Catenin Inhibition
por: Hu, Dong, et al.
Publicado: (2009)

Niclosamide is a potential therapeutic for familial adenomatosis polyposis by disrupting Axin-GSK3 interaction
por: Ahn, Sung Yong, et al.
Publicado: (2017)

Anti-helminthic niclosamide inhibits Ras-driven oncogenic transformation via activation of GSK-3
por: Ahn, Sung Yong, et al.
Publicado: (2017)

Novel Reporter Alleles of GSK-3α and GSK-3β
por: Barrell, William B., et al.
Publicado: (2012)

20(S)-protopanaxadiol promotes the migration, proliferation, and differentiation of neural stem cells by targeting GSK-3β in the Wnt/GSK-3β/β-catenin pathway
por: Lin, Kaili, et al.
Publicado: (2020)

GSK-3β and memory formation
por: Takashima, Akihiko
Publicado: (2012)

GSK3β and aging liver
por: Jin, Jingling, et al.
Publicado: (2009)

GSK3β and the aging kidney
por: Kreidberg, Jordan A., et al.
Publicado: (2022)

Cordycepin Regulates GSK-3β/β-Catenin Signaling in Human Leukemia Cells
por: Ko, Bor-Sheng, et al.
Publicado: (2013)

Fluoxetine Regulates Neurogenesis In Vitro Through Modulation of GSK-3β/β-Catenin Signaling
por: Hui, Jiaojie, et al.
Publicado: (2015)

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer
por: Arend, Rebecca C., et al.
Publicado: (2016)

Structural Plasticity of Dendritic Spines Requires GSK3α and GSK3β
por: Cymerman, Iwona A., et al.
Publicado: (2015)

GSK3α and GSK3β Phosphorylate Arc and Regulate its Degradation
por: Gozdz, Agata, et al.
Publicado: (2017)

Preclinical Identification of Sulfasalazine’s Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling
por: Leung, Wai-Hung, et al.
Publicado: (2022)

Correction: Kaushal et al. Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β. Cancers 2021, 13, 3105
por: Kaushal, Jyoti B., et al.
Publicado: (2021)

GSK3β loosens the CLASP on microtubules
por: Short, Ben
Publicado: (2009)

AKT/GSK3β Signaling in Glioblastoma
por: Majewska, Ewelina, et al.
Publicado: (2016)

Opposing Roles of GSK3α and GSK3β Phosphorylation in Platelet Function and Thrombosis
por: Moore, Samantha F., et al.
Publicado: (2021)

Wnt-signalling pathway in ovarian epithelial tumours: increased expression of β-catenin and GSK3β
por: Rask, K, et al.
Publicado: (2003)

Imperatorin promotes osteogenesis and suppresses osteoclast by activating AKT/GSK3 β/β‐catenin pathways
por: Yan, De‐Yi, et al.
Publicado: (2019)

Girdin acts as an oncogene in gastric cancer by regulating AKT/GSK3β/β-catenin signaling
por: Wang, Yun, et al.
Publicado: (2023)

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer
por: Arend, Rebecca C., et al.
Publicado: (2018)

Opposing roles of ICAT and Wnt/β-catenin signaling in NSC67657-induced monocytic differentiation
por: Wang, Weijia, et al.
Publicado: (2017)

14-3-3σ Regulates β-Catenin-Mediated Mouse Embryonic Stem Cell Proliferation by Sequestering GSK-3β
por: Chang, Tzu-Ching, et al.
Publicado: (2012)

Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/β-catenin and inducing mitochondrial dysfunctions
por: Zhao, Juan, et al.
Publicado: (2016)

Ras and Wnt Interaction Contribute in Prostate Cancer Bone Metastasis
por: Lin, Shian-Ren, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_269hqp7l5d7kkn8tafrtoctrcp